{
    "hands_on_practices": [
        {
            "introduction": "A fundamental skill in dermatology is distinguishing cutaneous signs of systemic disease from benign mimics. This exercise challenges you to differentiate jaundice, a hallmark of hepatobiliary dysfunction, from carotenaemia based on clinical findings and basic laboratory data. Mastering this distinction by applying principles of pigment deposition is crucial for avoiding unnecessary workups and correctly identifying patients who require urgent medical evaluation .",
            "id": "4428897",
            "problem": "A $52$-year-old vegan distance runner presents with progressive yellow-orange discoloration of the skin noticed over $3$ months. He reports no fatigue, abdominal pain, pruritus, or change in urine or stool color. On examination, there is prominent yellow-orange coloration of the palms, soles, and nasolabial folds. The sclerae and oral mucosa appear normally white and pink, respectively. Laboratory evaluation shows Aspartate Aminotransferase (AST) $28\\,\\mathrm{U/L}$, Alanine Aminotransferase (ALT) $32\\,\\mathrm{U/L}$, Alkaline Phosphatase (ALP) $95\\,\\mathrm{U/L}$, Gamma-Glutamyltransferase (GGT) $28\\,\\mathrm{U/L}$, total bilirubin $0.8\\,\\mathrm{mg/dL}$, direct bilirubin $0.2\\,\\mathrm{mg/dL}$, and Thyroid-Stimulating Hormone (TSH) $5.2\\,\\mathrm{mIU/L}$. He reports daily consumption of large quantities of carrot and pumpkin juices. \n\nUsing foundational principles of pigment deposition and bilirubin physiology, determine which option most strongly supports a diagnosis of cutaneous carotenaemia rather than jaundice. Choose the single best answer.\n\nA. Yellow-orange skin discoloration that spares sclera and mucous membranes, normal hepatic function tests, and a high intake of carotene-rich foods, with normal urine color and stool pigmentation.\n\nB. Dark urine, pale stools, scleral icterus, pruritus, and elevated direct bilirubin with raised ALP and GGT indicating cholestasis.\n\nC. Scleral icterus with elevated total bilirubin due to increased unconjugated bilirubin, dark urine absent, high Lactate Dehydrogenase (LDH) and reticulocytosis suggestive of hemolysis.\n\nD. Diffuse bronze hyperpigmentation accentuated in sun-exposed areas including buccal mucosa, orthostatic hypotension, hyponatremia, and low morning serum cortisol indicating primary adrenal insufficiency.\n\nE. Generalized pruritus with excoriations, xanthelasma, hypercholesterolemia, and elevated ALP consistent with chronic cholestatic liver disease.",
            "solution": "The user wants me to act as a meticulous STEM professor and solve a clinical problem.\n\n### Step 1: Extract Givens\n\n*   **Patient Profile:** $52$-year-old vegan distance runner.\n*   **Presentation:** Progressive yellow-orange skin discoloration for $3$ months.\n*   **Symptoms (absent):** No fatigue, abdominal pain, pruritus, or change in urine or stool color.\n*   **Physical Examination:**\n    *   Prominent yellow-orange coloration of palms, soles, and nasolabial folds.\n    *   Sclerae are white.\n    *   Oral mucosa is pink.\n*   **Laboratory Data:**\n    *   Aspartate Aminotransferase (AST): $28\\,\\mathrm{U/L}$\n    *   Alanine Aminotransferase (ALT): $32\\,\\mathrm{U/L}$\n    *   Alkaline Phosphatase (ALP): $95\\,\\mathrm{U/L}$\n    *   Gamma-Glutamyltransferase (GGT): $28\\,\\mathrm{U/L}$\n    *   Total bilirubin: $0.8\\,\\mathrm{mg/dL}$\n    *   Direct bilirubin: $0.2\\,\\mathrm{mg/dL}$\n    *   Thyroid-Stimulating Hormone (TSH): $5.2\\,\\mathrm{mIU/L}$\n*   **Dietary History:** Daily consumption of large quantities of carrot and pumpkin juices.\n*   **Question:** Determine which option most strongly supports a diagnosis of cutaneous carotenaemia rather than jaundice, based on principles of pigment deposition and bilirubin physiology.\n\n### Step 2: Validate Using Extracted Givens\n\nThe problem statement is evaluated against the validation criteria.\n\n*   **Scientifically Grounded:** The problem presents a classic clinical scenario. The distinction between carotenaemia and jaundice is a fundamental topic in internal medicine and dermatology. The signs, symptoms, and laboratory values are consistent with established medical knowledge. The pathophysiology of pigment deposition (bilirubin vs. carotenoids) is a well-understood scientific principle.\n*   **Well-Posed:** The problem is well-posed. It provides a detailed clinical vignette and asks for the constellation of findings that best supports one diagnosis (carotenaemia) over a key differential diagnosis (jaundice). The data provided are sufficient to make this distinction.\n*   **Objective:** The description of the patient's condition is objective, using standard medical terminology and quantitative lab results. It is free of subjective or biased language.\n\n### Step 3: Verdict and Action\n\nThe problem is **valid**. It is scientifically sound, well-posed, and objective. There are no contradictions, missing information, or other flaws. I will proceed with deriving the solution.\n\n### Derivation from First Principles\n\nThe core of this problem lies in differentiating between two causes of yellow skin discoloration: jaundice and carotenaemia. This requires understanding the distinct physiological properties and deposition patterns of the pigments involved.\n\n1.  **Jaundice (Icterus):**\n    *   **Pigment:** Bilirubin, a yellow breakdown product of heme.\n    *   **Pathophysiology:** Caused by hyperbilirubinemia, an elevated level of bilirubin in the blood (typically total bilirubin $>2.5-3\\,\\mathrm{mg/dL}$).\n    *   **Deposition:** Bilirubin has a high affinity for elastin, a protein abundant in connective tissues. Therefore, it deposits systemically in the skin, mucous membranes, and, most characteristically, the **sclerae** of the eyes. Scleral icterus (yellow sclerae) is a pathognomonic sign of jaundice and is often detectable before significant skin discoloration.\n    *   **Clinical Correlation:** In true jaundice, the sclerae will be yellow. Depending on the cause (pre-hepatic, hepatic, or post-hepatic), there may be other signs such as dark urine (from water-soluble conjugated bilirubin), pale stools (from biliary obstruction), pruritus (from bile salt deposition), and abnormal liver function tests.\n\n2.  **Carotenaemia:**\n    *   **Pigment:** Carotenoids (e.g., beta-carotene), which are lipid-soluble pigments found in many fruits and vegetables.\n    *   **Pathophysiology:** Caused by excessive intake of carotene-rich foods. The body's ability to metabolize and excrete the excess carotene is overwhelmed, leading to its accumulation in the blood (hypercarotenemia).\n    *   **Deposition:** Being lipophilic, carotenoids are deposited in tissues with high lipid content and are excreted in sebum and sweat. This leads to accumulation in the stratum corneum of the epidermis. The discoloration is therefore most prominent in areas where the stratum corneum is thickest (palms and soles) and where sebaceous glands are numerous (nasolabial folds).\n    *   **Clinical Correlation:** Crucially, the sclerae and mucous membranes lack a significant stratum corneum and have low lipid content, so they are **spared** from discoloration. This is the single most important clinical sign distinguishing carotenaemia from jaundice. Laboratory tests for liver function and bilirubin are normal. The condition is benign.\n\n### Application to the Provided Case\n\n*   **Clinical Findings:** The patient exhibits yellow-orange skin discoloration most prominent on the palms, soles, and nasolabial folds. This anatomical distribution is characteristic of carotenoid deposition. The finding of white sclerae and pink oral mucosa effectively rules out jaundice.\n*   **Laboratory Findings:** The patient's liver function tests (AST, ALT, ALP, GGT) and bilirubin levels (total and direct) are all within normal limits. This confirms the absence of hepatic disease or cholestasis, which would be the cause of jaundice.\n*   **Etiology:** The dietary history of high consumption of carrot and pumpkin juices provides a direct and sufficient cause for hypercarotenemia.\n*   **Other Factors:** The mildly elevated TSH ($5.2\\,\\mathrm{mIU/L}$, suggestive of subclinical hypothyroidism) can be a contributing factor, as thyroid hormone is necessary for the hepatic conversion of beta-carotene into vitamin A. Impaired conversion can lead to higher circulating levels of carotene. However, the primary cause is excessive intake.\n\n**Conclusion:** The combination of scleral sparing, characteristic skin discoloration pattern, normal liver and bilirubin labs, and a history of high carotene intake overwhelmingly supports the diagnosis of carotenaemia and argues against jaundice.\n\n### Option-by-Option Analysis\n\n*   **A. Yellow-orange skin discoloration that spares sclera and mucous membranes, normal hepatic function tests, and a high intake of carotene-rich foods, with normal urine color and stool pigmentation.**\n    *   **Analysis:** This option perfectly summarizes the key differentiating features of carotenaemia as derived from first principles and as seen in the patient vignette. Scleral sparing is the critical sign distinguishing it from jaundice. Normal hepatic function and bilirubin levels rule out a hepatobiliary cause. The dietary history provides the etiology. Normal urine/stool color further argues against a cholestatic process.\n    *   **Verdict:** **Correct**.\n\n*   **B. Dark urine, pale stools, scleral icterus, pruritus, and elevated direct bilirubin with raised ALP and GGT indicating cholestasis.**\n    *   **Analysis:** This option describes the classic signs and symptoms of post-hepatic (obstructive/cholestatic) jaundice. The presence of scleral icterus is definitive for jaundice, not carotenaemia. The lab findings are contrary to those presented in the case.\n    *   **Verdict:** **Incorrect**.\n\n*   **C. Scleral icterus with elevated total bilirubin due to increased unconjugated bilirubin, dark urine absent, high Lactate Dehydrogenase (LDH) and reticulocytosis suggestive of hemolysis.**\n    *   **Analysis:** This option describes the classic findings of pre-hepatic jaundice, typically caused by hemolysis. Again, the presence of scleral icterus indicates jaundice. The proposed mechanism (hemolysis) and lab findings are inconsistent with the patient's presentation.\n    *   **Verdict:** **Incorrect**.\n\n*   **D. Diffuse bronze hyperpigmentation accentuated in sun-exposed areas including buccal mucosa, orthostatic hypotension, hyponatremia, and low morning serum cortisol indicating primary adrenal insufficiency.**\n    *   **Analysis:** This option describes Addison's disease. The skin discoloration is \"bronze,\" not yellow-orange, involves mucous membranes (buccal mucosa), and is due to excess melanocyte-stimulating hormone (MSH) activity from a pro-opiomelanocortin (POMC) precursor. This is a completely different pathophysiology and clinical presentation.\n    *   **Verdict:** **Incorrect**.\n\n*   **E. Generalized pruritus with excoriations, xanthelasma, hypercholesterolemia, and elevated ALP consistent with chronic cholestatic liver disease.**\n    *   **Analysis:** This option describes signs associated with chronic cholestasis (e.g., primary biliary cholangitis), which would cause jaundice. The patient specifically lacks pruritus and has a normal ALP. Xanthelasma are lipid deposits but are associated with hypercholesterolemia in the context of liver disease, not carotenaemia.\n    *   **Verdict:** **Incorrect**.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "Beyond simply identifying the signs of liver disease, it is critical to assess its severity to guide prognosis and treatment. This problem requires you to apply the Child-Pugh scoring system, a cornerstone of hepatology, to a patient with decompensated cirrhosis. By integrating laboratory values with clinical observations, you will practice quantifying hepatic dysfunction and contextualizing classic cutaneous findings like spider angiomas within the broader picture of systemic disease .",
            "id": "4428865",
            "problem": "A patient with known alcohol-associated cirrhosis presents to a dermatology clinic for evaluation of progressive cutaneous changes. On examination, there are more than $15$ discrete spider telangiectases (spider angiomas) over the upper chest and face, symmetric palmar erythema, mild digital clubbing, and generalized xerosis with excoriations from pruritus. The patient reports intermittent confusion consistent with West Haven grade $2$ hepatic encephalopathy, currently controlled with lactulose and rifaximin, and has tense abdominal distention from ascites that has required repeated large-volume paracenteses despite maximal diuretic therapy. Laboratory testing on the day of evaluation shows a total bilirubin of $3.2\\,\\mathrm{mg/dL}$, a serum albumin of $2.9\\,\\mathrm{g/dL}$, and an International Normalized Ratio (INR) of $1.9$.\n\nUsing only well-established clinical criteria that synthesize hepatic synthetic function, excretory function, and the major complications of portal hypertension into a five-component severity score, determine the total points for this scoring system for this patient. In your reasoning, justify how the observed vascular stigmata (spider angiomas and palmar erythema) fit within the overall pattern of hepatic dysfunction reflected by the score. Provide only the total point value as your final answer, expressed as an integer with no units. No rounding is required.",
            "solution": "The problem statement is valid. It presents a coherent and scientifically grounded clinical scenario of a patient with decompensated cirrhosis and asks for the calculation of a score using well-defined clinical and laboratory parameters. The problem is self-contained, objective, and well-posed.\n\nThe problem requires the calculation of a total score using \"well-established clinical criteria that synthesize hepatic synthetic function, excretory function, and the major complications of portal hypertension into a five-component severity score.\" This description unambiguously refers to the Child-Pugh score, a prognostic tool used to assess the severity of chronic liver disease. The five components of this score are: total bilirubin, serum albumin, International Normalized Ratio (INR), ascites, and hepatic encephalopathy.\n\nThe scoring for each component is on a scale of $1$ to $3$ points, with higher points indicating greater severity. We will now evaluate the patient's data for each of the five components.\n\n1.  **Total Bilirubin**: This parameter assesses hepatic excretory function. The standard scoring is:\n    - $<2 \\ \\mathrm{mg/dL}$: $1$ point\n    - $2-3 \\ \\mathrm{mg/dL}$: $2$ points\n    - $>3 \\ \\mathrm{mg/dL}$: $3$ points\n    The patient's total bilirubin is $3.2\\,\\mathrm{mg/dL}$, which is greater than $3\\,\\mathrm{mg/dL}$. Therefore, the score for this component is $3$ points.\n\n2.  **Serum Albumin**: This parameter assesses hepatic synthetic function. The standard scoring is:\n    - $>3.5 \\ \\mathrm{g/dL}$: $1$ point\n    - $2.8-3.5 \\ \\mathrm{g/dL}$: $2$ points\n    - $<2.8 \\ \\mathrm{g/dL}$: $3$ points\n    The patient's serum albumin is $2.9\\,\\mathrm{g/dL}$, which falls within the range of $2.8-3.5\\,\\mathrm{g/dL}$. Therefore, the score for this component is $2$ points.\n\n3.  **International Normalized Ratio (INR)**: This parameter also assesses hepatic synthetic function, as the liver produces most coagulation factors. The standard scoring is:\n    - $<1.7$: $1$ point\n    - $1.7-2.3$: $2$ points\n    - $>2.3$: $3$ points\n    The patient's INR is $1.9$, which falls within the range of $1.7-2.3$. Therefore, the score for this component is $2$ points.\n\n4.  **Ascites**: This is a major complication of portal hypertension. The standard scoring is:\n    - None: $1$ point\n    - Mild to moderate (responsive to diuretics): $2$ points\n    - Severe or refractory (e.g., tense, requiring paracentesis): $3$ points\n    The patient has \"tense abdominal distention from ascites that has required repeated large-volume paracenteses.\" This constitutes severe/refractory ascites. Therefore, the score for this component is $3$ points.\n\n5.  **Hepatic Encephalopathy (HE)**: This is a major complication of hepatic insufficiency and portal hypertension. The standard scoring is based on the West Haven criteria:\n    - None (Grade $0$): $1$ point\n    - Grade $1-2$ (or controlled with medication): $2$ points\n    - Grade $3-4$ (or refractory): $3$ points\n    The patient has a history of intermittent \"West Haven grade $2$ hepatic encephalopathy.\" Therefore, the score for this component is $2$ points.\n\nTo determine the total score, we sum the points from each of the five components:\nTotal Score = (Points for Bilirubin) + (Points for Albumin) + (Points for INR) + (Points for Ascites) + (Points for HE)\nTotal Score = $3 + 2 + 2 + 3 + 2 = 12$ points.\n\nA total score of $10-15$ points corresponds to Child-Pugh Class C, indicating severe decompensated liver disease with a poor prognosis.\n\nThe problem also asks to justify how the observed vascular stigmata (spider angiomas and palmar erythema) fit within this pattern of hepatic dysfunction. These cutaneous findings, while not formal components of the Child-Pugh score, are classic physical manifestations of advanced liver disease and serve as qualitative indicators of the same underlying pathophysiology quantified by the score. The primary mechanism is thought to be an alteration in sex hormone metabolism. The failing liver is unable to adequately metabolize estrogens, leading to a state of relative hyperestrogenism. This elevated ratio of estrogen to androgen causes cutaneous arteriolar vasodilation. Spider angiomas (spider telangiectases) are composed of a central feeding arteriole with radiating superficial vessels, and palmar erythema is a blotchy redness of the palms, particularly the thenar and hypothenar eminences. The presence of numerous ($>5$) spider angiomas, as in this patient with more than $15$, is highly specific for cirrhosis. Thus, these vascular stigmata are direct clinical consequences of the same severe hepatic metabolic and synthetic failure reflected by the high bilirubin, low albumin, elevated INR, and the major complications of portal hypertension (ascites and encephalopathy). They are an external sign of the systemic disease state whose severity is numerically captured by the Child-Pugh score of $12$.",
            "answer": "$$\n\\boxed{12}\n$$"
        },
        {
            "introduction": "We now shift our focus from hepatic to renal pathology, addressing one of its most feared cutaneous complications: calcific uremic arteriolopathy (calciphylaxis). This practice demonstrates the direct link between disordered mineral metabolism in chronic kidney disease and the risk of vascular calcification. You will use a foundational biochemical calculation to assess risk, reinforcing the principle that simple laboratory data can be a powerful tool in predicting severe dermatologic outcomes .",
            "id": "4428899",
            "problem": "A middle-aged patient with advanced Chronic Kidney Disease (CKD) presents to dermatology with exquisitely painful, violaceous, retiform plaques on the thighs with evolving necrotic eschars. The clinical concern is for calcific uremic arteriolopathy (calciphylaxis), a cutaneous vascular calcification syndrome associated with disordered mineral metabolism in CKD. The biochemical risk surrogate used in clinical practice is the calcium-phosphate product, defined as the product of serum total calcium concentration and serum phosphorus concentration. Assume the following same-day laboratory values: serum total calcium $9.6$ $\\mathrm{mg}/\\mathrm{dL}$ and serum phosphorus $6.2$ $\\mathrm{mg}/\\mathrm{dL}$. Using the foundational definition that the calcium-phosphate product equals $[\\mathrm{Ca}] \\times [\\mathrm{P}]$, compute the calcium-phosphate product and compare it conceptually to the empirically used risk threshold of $55$ $\\mathrm{mg}^{2}/\\mathrm{dL}^{2}$ for calciphylaxis risk stratification in CKD. Express the computed product in $\\mathrm{mg}^{2}/\\mathrm{dL}^{2}$ and round to three significant figures. For the final numeric answer, report only the computed product as a number (no units), rounded to three significant figures.",
            "solution": "The problem presented is a straightforward calculation and conceptual comparison rooted in a well-defined clinical-biochemical context. I will first validate the problem statement according to the required procedure.\n\n### Step 1: Extract Givens\n- **Patient Profile**: Middle-aged with advanced Chronic Kidney Disease (CKD).\n- **Clinical Presentation**: Exquisitely painful, violaceous, retiform plaques on the thighs with evolving necrotic eschars.\n- **Clinical Concern**: Calcific uremic arteriolopathy (calciphylaxis).\n- **Definition**: The calcium-phosphate product is defined as $[\\mathrm{Ca}] \\times [\\mathrm{P}]$, where $[\\mathrm{Ca}]$ is the serum total calcium concentration and $[\\mathrm{P}]$ is the serum phosphorus concentration.\n- **Laboratory Value 1**: Serum total calcium, $[\\mathrm{Ca}] = 9.6 \\, \\mathrm{mg}/\\mathrm{dL}$.\n- **Laboratory Value 2**: Serum phosphorus, $[\\mathrm{P}] = 6.2 \\, \\mathrm{mg}/\\mathrm{dL}$.\n- **Risk Threshold**: An empirically used risk threshold for calciphylaxis is $55 \\, \\mathrm{mg}^{2}/\\mathrm{dL}^{2}$.\n- **Task**: Compute the calcium-phosphate product, express it in units of $\\mathrm{mg}^{2}/\\mathrm{dL}^{2}$, compare it conceptually to the risk threshold, and provide the final numeric value rounded to three significant figures.\n\n### Step 2: Validate Using Extracted Givens\n1.  **Scientifically Grounded**: The problem is scientifically sound. Calcific uremic arteriolopathy, or calciphylaxis, is a known and feared complication of end-stage renal disease. The dysregulation of mineral metabolism, particularly involving calcium and phosphorus, is a central pathogenetic factor. The calcium-phosphate product is a long-standing, albeit imperfect, clinical tool used to assess the risk of extraskeletal calcification. The provided laboratory values for calcium and phosphorus are clinically realistic for a patient with advanced CKD. The stated risk threshold of $55 \\, \\mathrm{mg}^{2}/\\mathrm{dL}^{2}$ is a widely cited value in nephrology and dermatology literature.\n2.  **Well-Posed**: The problem is well-posed. It provides an explicit formula for the quantity to be calculated, supplies all necessary numerical inputs, and gives clear instructions for units and rounding. A unique solution exists.\n3.  **Objective**: The language is clinical and objective. It describes a medical scenario and requests a specific calculation based on provided data and definitions. It is free from subjective claims.\n\n### Step 3: Verdict and Action\nThe problem is deemed **valid**. It is scientifically grounded, well-posed, and objective. It represents a a direct application of a defined biochemical formula to clinical data. I will proceed with the solution.\n\n### Solution\nThe problem requires the calculation of the calcium-phosphate product for a patient with Chronic Kidney Disease (CKD) and a clinical presentation suggestive of calcific uremic arteriolopathy. The product is then to be compared to a clinical risk threshold.\n\nLet $[\\mathrm{Ca}]$ denote the serum total calcium concentration and $[\\mathrm{P}]$ denote the serum phosphorus concentration. The calcium-phosphate product, which we shall denote as $C_p$, is defined by the relation:\n$$\nC_p = [\\mathrm{Ca}] \\times [\\mathrm{P}]\n$$\n\nThe given laboratory values are:\n$$\n[\\mathrm{Ca}] = 9.6 \\, \\frac{\\mathrm{mg}}{\\mathrm{dL}}\n$$\n$$\n[\\mathrm{P}] = 6.2 \\, \\frac{\\mathrm{mg}}{\\mathrm{dL}}\n$$\n\nSubstituting these values into the defining equation for the calcium-phosphate product:\n$$\nC_p = \\left(9.6 \\, \\frac{\\mathrm{mg}}{\\mathrm{dL}}\\right) \\times \\left(6.2 \\, \\frac{\\mathrm{mg}}{\\mathrm{dL}}\\right)\n$$\n\nThe numerical calculation is performed as follows:\n$$\n9.6 \\times 6.2 = 59.52\n$$\n\nThe units multiply accordingly:\n$$\n\\frac{\\mathrm{mg}}{\\mathrm{dL}} \\times \\frac{\\mathrm{mg}}{\\mathrm{dL}} = \\frac{\\mathrm{mg}^{2}}{\\mathrm{dL}^{2}}\n$$\n\nTherefore, the patient's calcium-phosphate product is:\n$$\nC_p = 59.52 \\, \\frac{\\mathrm{mg}^{2}}{\\mathrm{dL}^{2}}\n$$\n\nThe problem requires a conceptual comparison of this computed value to the empirically used risk threshold of $55 \\, \\mathrm{mg}^{2}/\\mathrm{dL}^{2}$. The patient's product of $59.52 \\, \\mathrm{mg}^{2}/\\mathrm{dL}^{2}$ is greater than the threshold value of $55 \\, \\mathrm{mg}^{2}/\\mathrm{dL}^{2}$. This elevated product indicates a state of significant hyperphosphatemia relative to the serum calcium level, creating a physicochemical environment that favors the precipitation of calcium phosphate salts in soft tissues, including the media of small and medium-sized arteries. This finding is therefore consistent with the clinical suspicion of calcific uremic arteriolopathy, providing biochemical evidence that supports the diagnosis.\n\nFinally, the problem statement requires that the final numeric answer be rounded to three significant figures. The calculated value is $59.52$. The first three significant figures are $5$, $9$, and $5$. The fourth significant digit is $2$, which is less than $5$, so we round down (truncate).\n$$\nC_p \\approx 59.5 \\, \\frac{\\mathrm{mg}^{2}}{\\mathrm{dL}^{2}}\n$$\nThe final reported number should be $59.5$.",
            "answer": "$$\n\\boxed{59.5}\n$$"
        }
    ]
}